The Magazine for Sleep Professionals
Monday, September 28, 2026
Inspire Medical Systems, Inc. announced that the United States Food and Drug Administration (FDA) has approved additional magnetic resonance imaging (MRI) scan conditions for use with Inspire therapy. This full-body MRI approval expands the Inspire use labeling that previously allowed only head, neck, and extremity MRI scans. Most importantly, this […]
Inspire Medical Systems, Inc. (“Inspire”) reported equity investments in two private companies, EnsoData, Inc. in Madison, WI, and Ognomy Inc. in Buffalo, NY. EnsoData increases sleep lab capacity and efficiency with their FDA-approved sleep study analysis platform, EnsoSleep. Using waveform Artificial Intelligence (AI), EnsoSleep automates the scoring and analysis of […]
Inspire Medical Systems, Inc. is providing an update on the 2022 Reimbursement payment rates for Inspire procedures performed in Ambulatory Surgical Centers (ASCs). The Centers for Medicare and Medicaid Services (CMS) today published updated addendum files for the 2022 ASC payment system, including updating the assigned device offset percentage and […]
Two-incision approach reduces average procedure time by approximately 20 percent Inspire Medical Systems, Inc. has announced receipt of U.S. Food and Drug Administration (“FDA”) approval for an improved surgical implant procedure that eliminates one incision with a revised placement of the pressure sensing lead. This newly approved procedure will reduce […]
Inspire Medical Systems, Inc. (“Inspire”) announced today that Cigna, one of the leading health plans in the United States, will provide coverage for the Company’s Inspire therapy (hypoglossal nerve neurostimulation), effective June 15, 2020. Cigna Corporation is a global health service company that provides health insurance coverage for approximately 16 […]
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has approved an expanded age range for Inspire therapy to include 18-21-year-old patients, as compared to the previous minimum age requirement for patients to be 22 years old. Following a detailed review of the clinical evidence […]
Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced that three Medicare Administrative Contractors (“MACs”) have announced the effective release date of March 15, 2020, for their final Local Coverage Decision […]
Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that two draft Local Coverage Determinations (LCDs) were published proposing coverage of Inspire therapy. The proposed draft LCDs are available on the Medicare […]
Inspire Medical Systems, Inc., developers of the Inspire hypoglossal nerve stimulator, a minimally invasive solution for patients with obstructive sleep apnea (“OSA”), recently revealed its new brand identity and launched a new website. “While our name and focus on patient outcomes remain the same, our brand identity and website, InspireSleep.com, have […]
